Compare INVZ & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INVZ | ENGN |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | Israel | Canada |
| Employees | 415 | 82 |
| Industry | Auto Parts:O.E.M. | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.1M | 117.2M |
| IPO Year | N/A | N/A |
| Metric | INVZ | ENGN |
|---|---|---|
| Price | $0.64 | $1.88 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $2.68 | ★ $21.08 |
| AVG Volume (30 Days) | ★ 3.3M | 1.2M |
| Earning Date | 05-14-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $29.61 | N/A |
| Revenue Next Year | $53.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $1.40 |
| 52 Week High | $2.54 | $12.25 |
| Indicator | INVZ | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 45.69 | 43.73 |
| Support Level | $0.59 | $1.68 |
| Resistance Level | $0.74 | $7.92 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.01 | 0.10 |
| Stochastic Oscillator | 36.50 | 73.21 |
Innoviz Technologies Ltd is a provider of solid-state LiDAR and perception solutions that feature technological breakthroughs across core components and bring enhanced vision and superior performance to enable safe autonomous driving at a mass scale. The company provides a complete and comprehensive solution for OEMs and Tier-1 partners that are developing and marketing autonomous driving vehicles to the passenger cars and other relevant markets, such as robotaxis, shuttles, delivery vehicles, buses and trucks and other industries that require 3-dimensional high resolution sensors. Company's solutions can enable safe autonomy for industries like logistics, drones, robotics, construction and other industrial applications, agriculture, smart city, smart infrastructure, security and mapping.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.